Inspire Pharma

Yet another biotech that presented to investors last week was Inspire Pharma. Here is a summary of the points they made:

1) They have treatments for Opthamology and Pulmonary problems

2) They have two drugs in stage III testing (one for dry eye and one for Cystic Fibrosis)

3) The test of the Cystic Fibrosus drug (Denofosol) indicated that the drug improved the patient's condition to a statistically significantly amount

4) The dry eye drug market has about 30,000,000 possible patients

5) The stock offering placed in August was oversubscribed

6) Revenues:
2004 $11,000,000
2007 $49,000,000
2009 $80,000,000 to 90,000,000 estimated